NCT07296484招募中2 期
Clofutriben And Placebo Phase 2 Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Sparrow Pharmaceuticals100 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2025年11月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
- 试验地点
- 100
- 主要终点
- Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
研究概览
简要总结
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
详细描述
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •From Screening 1
- •Age at least 18 years.
- •HbA1c ≥7.5% documented within 3 months prior to Screening
- •(The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
- •Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
- •Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day
- •Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
- •At least one of the following
- •≥3 stable and adequate ADMs;
- •diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- •hypertension requiring ≥2 adequately dosed AHMs;
- •adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- •adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- •evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- •or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
- •At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
- •At Screening 2
- •HbA1c ≥7.5% at Screening
- •No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
排除标准
- •New-onset diabetes (onset <1 year in the past).
- •Unwillingness to maintain with current glucose-lowering regimen during the trial.
- •Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
- •Unwillingness to comply with CGM or other trial procedures.
- •Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
- •Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
- •Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
- •Any of the following in medical history:
- •Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- •A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- •Hypersensitivity or severe reaction to dexamethasone;
- •Pheochromocytoma, or suspicion thereof;
- •Anorexia, or other eating disorder;
- •Glucocorticoid resistance;
- •Multiple sclerosis;
- •Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- •Idiopathic thrombocytopenic purpura;
- •Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- •Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- •Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- •Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- •Any of the following in medication history:
- •Any of the excluded medications listed in Section 6.9;
- •Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- •Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- •Pregnancy (including a positive urine test) or current breast feeding.
- •From Screening 2
- •Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- •wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- •a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- •supraclavicular/dorsocervical fat accumulation;
- •irounding of the face (especially compared with prior photos);
- •skin changes (violaceous striae, skin thinning, or excessive bruising);
- •proximal muscle weakness on exam; or
- •history of deep vein thrombosis/pulmonary embolism.
- •Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- •Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- •Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- •Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- •Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- •Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- •Known hypersensitivity to clofutriben or to any of the product
研究组 & 干预措施
placebo
Placebo Comparator
placebo control oral tablet daily
干预措施: Placebo (Drug)
Dose 4
Experimental
clofutriben 12 mg oral tablet daily
干预措施: clofutriben (Drug)
Dose 3
Experimental
clofutriben 6mg oral tablet daily
干预措施: clofutriben (Drug)
Dose 2
Experimental
clofutriben 2mg oral tablet daily
干预措施: clofutriben (Drug)
Dose 1
Experimental
clofutriben .2 mg oral tablet daily
干预措施: clofutriben (Drug)
结局指标
主要结局
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
时间窗: 8-10 hours after the dexamethasone 1 mg dose.
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
时间窗: 24 weeks.
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.
次要结局
- Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.(24 weeks)
研究者
研究点 (100)
Loading locations...
相似试验
招募中
1 期
A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesType 2 DiabetesHealthy VolunteerNCT07270731Novo Nordisk A/S60
终止
1 期
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00637338Pfizer42
已完成
2 期
A Study for Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00871572Eli Lilly and Company87
招募中
2 期
Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)NCT07286747University Hospital Schleswig-Holstein390
已完成
1 期
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)Healthy VolunteerNCT01018823Merck Sharp & Dohme LLC40